Search the Newsreel

Tarsus Pharmaceuticals (TARS) Projected to Release Earnings on Thursday

Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Tarsus Pharmaceuticals, Inc. (TARS) is projected to report a year-over-year increase in earnings and higher revenues for Q2 2026, though a negative Earnings ESP and Zacks Rank #4 suggest it might not beat consensus EPS estimates. Analysts have become more bearish on the company's …

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme

Shares of Tarsus Pharmaceuticals (TARS) fell about 5% after Culper Research accused the company of using an illegal Medicare copay scheme to boost sales of its product, XDEMVY. Culper claims Tarsus inflates its total addressable market and will miss 2026 guidance. Retail traders, however, …

Tarsus Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:TARS

Tarsus Pharmaceuticals, Inc. (TARS) generated $451.36 million USD in revenue last year, primarily from its Therapeutics segment. This represents a significant increase from the previous year's $182.95 million USD. The entire revenue for the company came from the United States market.

How Tarsus Pharmaceuticals Inc. (TARS) Affects Rotational Strategy Timing

This article analyzes Tarsus Pharmaceuticals Inc. (TARS) through the lens of quantitative research and AI models to provide insights for rotational strategy timing. It identifies a neutral sentiment in the near term, a mid-channel oscillation pattern, and highlights an exceptional risk-reward setup. The analysis …

Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89

Guggenheim has lowered its price target for Tarsus Pharmaceuticals (NASDAQ: TARS) to $89 from $90, while maintaining a Buy rating. The company's Xdemvy launch is supported by strong sales and marketing, leading to significant prescription growth and revenue momentum. Tarsus also recently acquired iRenix …

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Tarsus Pharmaceuticals announced an executive leadership transition with Aziz Mottiwala, Chief Commercial Officer, departing to become CEO of a public medical device company. Neera Clase, Senior Vice President of Market Access, has been appointed Interim Chief Commercial Officer. This transition occurs as Tarsus enters …

Tarsus Pharmaceuticals Announces Executive Leadership Transition

Tarsus Pharmaceuticals has announced a leadership transition where Neera Clase, previously senior vice president of market access, will serve as interim chief commercial officer. This follows the departure of Aziz Mottiwala, who is leaving to become CEO of a public medical device company. The …